Topical Treatment for Sexual Pain, Vulvar Pain, in Postmenopausal Women Not Taking Estrogens or Similiar Hormones. Women on Aromatase Inhibitors or Tamoxifen CAN Enter the Clinical Trial
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03682601 |
|
Recruitment Status :
Recruiting
First Posted : September 24, 2018
Last Update Posted : September 24, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Sexual Pain Disorders Postmenopausal Symptoms Vulvovaginal Atrophy Female Sexual Dysfunction Dyspareunia Vulvodynia Vestibulodynia Arousal Disorders, Sexual | Drug: Sinecatechins Topical Other: Placebo | Phase 2 |
Topical Veregen (15% sinecatechins) is an FDA approved botanical drug derived from green tea and is approved to be used as multiple doses, three times a day to treat all visible external genital warts.
Topical green tea ointment has been shown to alleviate pain and improve wound healing in the vulvar vestibule for women who have had a recent episiotomy in the medical literature. In private clinical practice, dilute Veregen (7.5% sinecatechins) has been effective in alleviating , sexual pain, vulvar vestibular pain, dyspareunia, in postmenopausal women as well as improving overall sexual satisfaction,( increasing lubrication, arousal and quality of orgasm). In this study, dilute Veregen, (7.5% sinecatechins) or placebo is being applied, as a single dose, topically, once a day, to alleviate pain in the vulvar vestibule upon sexual contact or dyspareunia in postmenopausal women who are not being treated with any form of estrogen or other hormonal treatments. Please note that women taking aromatase inhibitors,tamoxifen, SERMS, CAN enter the Clinical Trial.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Randomized, Double Blinded, Placebo Controlled |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Double Blinded |
| Primary Purpose: | Treatment |
| Official Title: | 7.5% Sinecatechins Ointment, a Botanical Drug Derived From Green Tea, for the Treatment of Significant to Severe Secondary Provoked Vestibulodynia in Sexually Active, Post-Menopausal Women With Vulvovaginal Atrophy |
| Actual Study Start Date : | August 30, 2018 |
| Estimated Primary Completion Date : | July 30, 2020 |
| Estimated Study Completion Date : | September 30, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
30 postmenopausal women not using estrogen will apply a 1/2 inch strand of Placebo ointment once daily to their vulvar vestibule for a total of 6 weeks. They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain). A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy. The participant will fill out questionnaires during office visits with the gynecologist. In addition, 2 short questionnaires will be filled out online on a HIPAA compliant web based survey at the end of week 1,2,4 and 5. |
Other: Placebo
Aquaphor |
|
Active Comparator: 7.5% Topical sinecatechins ointment
30 postmenopausal women not using estrogen will apply a 1/2 inch strand of 7.5% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 6 weeks. They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain). A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy. The participant will fill out questionnaires during office visits with the gynecologist. In addition, 2 short questionnaires will be filled out online on a HIPAA compliant web based survey at the end of week 1,2,4 and 5. |
Drug: Sinecatechins Topical
Topical sinecatechins ointment will be applied daily.
Other Name: Veregen |
- Numerical Rating Scale for pain [ Time Frame: Change in the Numerical Rating Scale for pain will be assessed weekly for 6 weeks and then finally at the end of week 8 ]Subjects will be asked to rate their pain 0=no pain, 1-3= mild pain, 4-6 =moderate pain; 7-9= significant pain and 10= severe pain
- Female Sexual Function Index Questionnaire; [ Time Frame: to be answered at the initial office visit, then at the end of 3 weeks, then at the end of 6 weeks, and then at the end of 8 weeks ]19 questions (6 domains: Desire, Arousal, Lubrication, Orgasm, Satisfaction, Pain). 2 questions for Desire score range 1-5, The sum is multiplied by 0.6 with subscale score range 1.2 to 6.0; 4 questions for Arousal with score range 0-5. The sum is multiplied by 0.3 with a subscale score range 0-6; 4 questions for Lubrication with score range from 0-5. The sum is multiplied by 0.3 with a subscale score range 0-6; 3 questions in the Orgasm with score range from 0-5. The sum is multiplied by 0.4 with a subscale score range from 0-6 ; 4 questions in Satisfaction, 2 questions with a score range 0-5 and 2 questions with a score range 1-5. The sum is multiplied by 0.4 with a subscale score range 0-6; 3 questions in the Pain with score range 0-5. The sum is multiplied by 0.4 with a subscale score 0-6. The Total score 1.2-36.0 equals sum of subscale scores. Lower values are a worse outcome. A Total score of < or= to 26.55 equals Female Sexual Dysfunction.
- Female Sexual Distress Questionnaire revised [ Time Frame: to be answered at the initial office visit, then at the end of 3 weeks, then at the end of 6 weeks, and then at the end of 8 weeks ]There are 13 questions to evaluate the level of sexual distress being. For each question the scale range is from 0 - 4. The total score is the derived from the sum of the individual scores from each of the 19 questions. A score of 11 or higher indicates sexual distress.
- Vulvovaginal Symptoms Questionnaire [ Time Frame: to be answered at the initial office visit, then at the end of 3 weeks, then at the end of 6 weeks, and then at the end of 8 weeks ]There are Yes or No questions to evaluate characteristics of symptoms subject is experiencing. The scale range for each question is 0-1. No is scored as 0 and Yes is scored as 1. Higher scores indicate that the subject is experiencing more vulvovaginal symptoms
- Sexual Activities Log [ Time Frame: To be answered at the initial office visit then at the end of each week for 6 weeks and then at the end of week 8 ]Questionnaire to determine, level of sexual desire, distress about level of sexual desire, whether a subject engaged in sexual activity, frequency of sexual activity, satisfaction with sexual activity, and whether a subject had an orgasm during sexual activity during the past week. Question 1 has a scale range from 0-3. For question 1 a higher value indicates more sexual desire. Question 2 has a scale range from 0-4. For question 2 a higher value indicates more distress over level of sexual desire. Question 3 has scale range of 0-1 and is a yes or no question about masturbation; Question 4 asks the number of times that the subject had sex during the past week and has a minimum score of 0 and no maximum score. Questions 5 and 6 are Yes or No questions with a 0-1 scale range. Question 5 asks about was sex satisfying. Question 6 asks about whether the subject has an orgasm. The scores to the questions are not combined but reported individually.
- Vaginal pH [ Time Frame: To be performed at each office visit , the first office visit; at the end of the 3rd week office visit, at the end of the 6th week office visit ]A vaginal speculum exam will be performed by the gynecologist to evaluate with a pH paper the vaginal pH
- Vaginal maturation index [ Time Frame: To be performed twice, once at the first office visit and then at the end of the 6th week office visit ]A vaginal speculum exam will be performed by the gynecologist and a gentle swabbing of the lateral vaginal wall will be performed to assess the degree of vaginal atrophy in the postmenopausal subject
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | Participant must be a postmenopausal female who has not menstruated for at least one year either because of surgical removal of ovaries and uterus or because of natural menopause. Women taking tamoxifen CAN enter the clinical trial. |
| Accepts Healthy Volunteers: | Yes |
Inclusion Postmenopausal women
Generally healthy women must meet the following eligibility criteria:
- For surgically menopausal women, be 20-70 years of age and at least 12 months post menopause.
- For naturally postmenopausal women, be 40-70 years of age and at least 1 year post menopause (defined as no spontaneous menses for 1 year).
- In screening their vaginal pH will be 4.6 or greater and their vaginal maturation index will be consistent with vaginal atrophy. Vaginal atrophy is thinning, drying and of the vaginal walls due to having less estrogen in the body.
- Be, sexually functional, both psychologically and physically, whereby a woman is to be psychologically interested in sexual activity and physically sexually active with regular vestibular including vaginal introital genital manipulation whether through masturbation or partner sex, whether using digits, oral sexual contact, sex toys, and/or penile penetration present at regular intervals each month during the 4-week pre-treatment and the 6- week active treatment period of the study and ending at the 8th- week of their participation in the study.
- Be able and willing to participate in the study as evidenced by providing written informed consent.
-
Answer affirmatively to ALL of the following questions:
- Before your vulvar pain, would you say that in general, your sex life was good and satisfying?
- Since you have been experiencing vulvar pain, do you feel you have experienced a meaningful loss in your desire for sex?
- Since experiencing vulvar pain, do you feel you have experienced a significant decrease in your sexual activity?
- Are you concerned or bothered by your current level of desire for or interest in sex?
- Would you like to see an increase in your level of interest or desire for sex and sexual activity?
- Women taking aromatase inhibitors or tamoxifen CAN enter the clinical trial
Exclusion Criteria:
- Have taken estrogen-containing treatments, either by systemic or local route, for three months or more.
- Have any physical limitations or sexual trauma that would interfere with normal sexual function.
-
Have used estrogen, including vaginal conjugated equine estrogen, or estrogen progestin therapy, vaginal oestriol or low-dose vaginal oestradiol or any other exogenous estrogenic compound pharmaceutical including OTC plant based estrogenic substances in the last 12 weeks. Have used tablet or powder forms of phyto-estrogens for less than 12 weeks prior to Visit 1 (Week 0).
NOTE: Women taking aromatase inhibitors or tamoxifen CAN enter the clinical trial.
- Have used within the last 12 weeks any of the following medications/preparations that may interfere with the study purpose: systemic corticosteroids (acute use for fewer than 7 days is accepted), SSRI's, tricyclic antidepressants, anti-androgens, spironolactone, PDE5 inhibitors (Viagra ®).
- Have occasionally used (averaging more than once a week) in the past 30 days the following preparations that may interfere with the study purpose: DHEA or other drugs or supplements that may, in the opinion of the Investigator, affect sexual function.
- Be experiencing any chronic or acute life stress relating to any major life change, such as recent loss of income or the death of a close family member, that may, in the opinion of the Investigator, significantly interfere with sexual function.
- Have significant psychiatric disorder, a significant alcohol or drug dependency and/or be receiving pharmacologic treatment for such illness or disorder.
- Have evidence of clinically significant organic disorder on the history and/or physical examination that would, in the opinion of the Investigator, put the patient at risk, present the patient from completing the study, or otherwise affect the outcome of the study.
- Have a history of genital herpes because of the episodic nature of genital herpes and of the known possibility of occurrence of herpetic pain without visible dermatologic manifestations of herpes. Genital herpes and its accompanying genital pain may obscure the source of the genital pain experienced and confound the ability to determine the efficacy of treatment/placebo on endpoint of alleviation of pain in women with SPVD.
- Have any infection of the genitalia
- Have lichen sclerosis, lichen planus, contact dermatitis, psoriasis or any inflammatory condition or abrasions of the vulva
- Have an episiotomy scar in the area where pain is perceived as it may confound the etiology of the perceived pain
-
Have diabetes.
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03682601
| Contact: Lila Nachtigall, M.D. | 212-779-8353 | doctorlila@gmail.com | |
| Contact: Fred Naftolin, M.D. | 212-779-8353 | Frederick.Naftolin@nyulangone.org |
| United States, New York | |
| Lila Nachtigall, M.D. | Recruiting |
| New York, New York, United States, 10016 | |
| Contact: Lila Nachtigall, M.D. 212-779-8353 doctorlila@gmail.com | |
| Contact: Amy Meadow, PA 212-779-8353 Clinicaltrialpa@gmail.com | |
| Sub-Investigator: Dena Harris, M.D. | |
| Principal Investigator: Lila Nachtigall, M.D. | |
| Miriam Greene, M.D. | Recruiting |
| New York, New York, United States, 10016 | |
| Contact: Miriam Greene, M.D. 212-725-3966 m.greenemd@aol.com | |
| Contact: Amy Meadow, P.A. Clinicaltrialpa@gmail.com | |
| Principal Investigator: Miriam Greene, M.D. | |
| Elizabeth Eden, M.D. | Recruiting |
| New York, New York, United States, 10022 | |
| Contact: Elizabeth Eden, M.D. 212-355-7103 dr.elizabetheden@gmail.com | |
| Contact: Amy Meadow, P.A. Clinicaltrialpa@gmail.com | |
| Principal Investigator: Elizabeth Eden, M.D. | |
| Cynthia Krause, M.D. | Recruiting |
| New York, New York, United States, 10128 | |
| Contact: Cynthia Krause, M.D. 212-369-0602 info@cynthiakrausemd.com | |
| Contact: Amy Meadow, P.A. Clinicaltrialpa@gmail.com | |
| Principal Investigator: Cynthia Krause, M.D. | |
| Janis Enzenbacher, M.D. | Recruiting |
| Nyack, New York, United States, 10960 | |
| Contact: Janis Enzenbacher, M.D. 914-325-1664 janiszen@drgyn.us | |
| Contact: Amy Meadow, P.A. Clinicaltrialpa@gmail.com | |
| Principal Investigator: Janis Enzenbacher, M.D. | |
Documents provided by Lila Nachtigall, M.D., Dr. Lila Nachtigall Rapid Medical Research, New York:
Publications:
| Responsible Party: | Lila Nachtigall, M.D., Lila Nachtigall, M.D., Professor of Gynecology, Dr. Lila Nachtigall Rapid Medical Research, New York |
| ClinicalTrials.gov Identifier: | NCT03682601 History of Changes |
| Other Study ID Numbers: |
GTO1 |
| First Posted: | September 24, 2018 Key Record Dates |
| Last Update Posted: | September 24, 2019 |
| Last Verified: | September 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
Sexual Pain Postmenopausal Symptoms Vulvovaginal Atrophy Vulvodynia |
Dyspareunia Vestibulodynia Female Sexual Dysfunction Arousal Disorders, Sexual |
|
Vulvodynia Dyspareunia Vulvar Vestibulitis Disease Atrophy Somatoform Disorders Sexual Dysfunctions, Psychological Pathologic Processes Pathological Conditions, Anatomical Vulvar Diseases |
Genital Diseases, Female Sexual Dysfunction, Physiological Genital Diseases, Male Mental Disorders Vulvitis Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |